NEW YORK (GenomeWeb News) – The pharmaceutical firm Janssen R&D has teamed up with the Multiple Myeloma Research Foundation to help MMRF and its partners pursue their Personalized Medicine Initiative, part of which is a large clinical and molecular profiling study.

MMRF said today that Janssen has joined its pre-competitive consortium, a group of partners that support the PMI and its Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile, or CoMMpass, program. The PCC partners provide both scientific and financial support for the initiative.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.